keyword
MENU ▼
Read by QxMD icon Read
search

oncology lymphoma

keyword
https://www.readbyqxmd.com/read/28718335/variability-of-performance-status-assessment-between-patients-with-hematologic-malignancies-and-their-physicians
#1
Alexis D Leal, Cristine Allmer, Matthew J Maurer, Tait D Shanafelt, James R Cerhan, Brian K Link, Carrie A Thompson
This study was conducted to determine the incidence of inter-observer variability in Eastern Cooperative Oncology Group (ECOG) performance status (PS) rating between patients with leukemia and lymphoma and their physicians. ECOG PS was assessed at diagnosis by patients and their physicians and stratified by disease subtype, gender, age, disease stage and education. Association between patient- and physician-rated PS and overall survival (OS) was stratified by subtype and prognostic risk score. Overall, 65% of patients and physicians rated PS the same...
July 18, 2017: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/28717759/quality-oncology-practice-initiative-can-guide-and-improve-oncology-providers-training-in-brazil
#2
Cristiane Decat Bergerot, Errol J Philip, Paulo Gustavo Bergerot, Simone Elias, Daiane Pereira Guimarães, Nora Manoukian Forones, Otavio Cesar Carvalho Guimarães Baiocchi, Nildo Alves Batista, Edvane Birelo Lopes De Domenico
PURPOSE: It has become crucial to translate scientific findings and to find ways by which to mobilize local resources to improve the quality and accessibility of cancer care in developing countries. This study seeks to provide insight into challenge through examining differences in clinician documentation of patients with cancer treated at a Brazilian Public University Hospital. METHODS: ASCO Quality Oncology Practice Initiative (QOPI) measures were used to examine the care provided in the departments of breast, colorectal, lymphoma, gynecology, and lung cancers...
June 2017: Journal of Global Oncology
https://www.readbyqxmd.com/read/28711571/effectiveness-of-single-dose-rasburicase-in-patients-with-lymphoid-malignancies-at-a-high-risk-for-tumor-lysis-syndrome
#3
Young-Woo Jeon, Dae-Hun Kwak, Sung-Soo Park, Jae-Ho Yoon, Sung-Eun Lee, Ki-Seong Eom, Yoo-Jin Kim, Hee-Je Kim, Seok Lee, Chang-Ki Min, Jong-Wook Lee, Woo-Sung Min, Seok-Goo Cho
BACKGROUND: Tumor lysis syndrome (TLS) is a life-threatening disorder that occurs mainly in patients with high-tumor burden hemato-oncologic malignancies. It results in metabolic derangements, including hyperuricemia and acute renal failure. The powerful management for TLS is a daily dose of rasburicase for up to 5 days before chemotherapy; however, the optimal dose and duration of rasburicase for TLS prophylaxis have not been standardized for patients at high risk for TLS. Therefore, we evaluated the efficacy of single-dose rasburicase for prophylactic purposes in patients with malignant lymphoma at high risk for TLS...
June 27, 2017: Clinical Lymphoma, Myeloma & Leukemia
https://www.readbyqxmd.com/read/28702411/diffuse-large-b-cell-lymphoma-in-elderly-experience-from-a-tertiary-care-oncology-center-in-south-india
#4
K N Lokesh, M C Suresh Babu, K C Lakshmaiah, K Govind Babu, Smitha C Saldanha, D Loknatha, Linu Abraham Jacob, S Vishwanath, C S Premalatha, P R Kiran
INTRODUCTION: Diffuse large B-cell lymphoma (DLBCL) is the most frequent non-Hodgkins lymphoma in the elderly. With the rising proportion of older persons in India, it is important to study current patterns and management of this disease, given that data in this regard are scarce in Indian settings. The aim of this study was to document the clinical features of DLBCL among elderly patients and their outcome over 7 years at a tertiary care oncology center. MATERIALS AND METHODS: This was a retrospective records review of 119 DLBCL cases between January 2007 and January 2015 aged 60 years and above done at Kidwai Memorial Institute of Oncology, Bengaluru, Karnataka, India...
April 2017: South Asian Journal of Cancer
https://www.readbyqxmd.com/read/28702410/plasmablastic-lymphoma-in-immunocompetent-and-in-immunocompromised-patients-experience-at-a-regional-cancer-centre-in-india
#5
A H Rudresha, K C Lakshmaiah, Ankit Agarwal, K Govind Babu, D Loknatha, Linu Abraham Jacob, Suresh Babu, K N Lokesh, L K Rajeev
INTRODUCTION: Plasmablastic lymphoma (PBL) is a rare lymphoma associated with immunosuppression. It is strongly associated with immunosuppression (human immunodeficiency virus [HIV]) and often occurs within the oral cavity. PBL is also seen in patients receiving immunosuppressive therapy; however, despite its predisposition for the immunocompromised patients, PBL has been diagnosed in immunocompetent patients. AIM: This study aims to prognostic factors and outcome of PBL in immunocompromised and in immunocompetent patients...
April 2017: South Asian Journal of Cancer
https://www.readbyqxmd.com/read/28701224/the-150-most-important-questions-in-cancer-research-and-clinical-oncology-series-questions-40-49
#6
EDITORIAL
(no author information available yet)
Since the beginning of 2017, Chinese Journal of Cancer has published a series of important questions in cancer research and clinical oncology, which sparkle diverse thoughts, interesting communications, and potential collaborations among researchers all over the world. In this article, 10 more questions are presented as followed. Question 40. Why do mice being used as tumorigenesis models raised in different places or different conditions possess different tumor formation rate? Question 41. How could we generate more effective anti-metastasis drugs? Question 42...
July 13, 2017: Chinese Journal of Cancer
https://www.readbyqxmd.com/read/28700812/disparities-in-location-of-death-of-adolescents-and-young-adults-with-cancer-a-longitudinal-population-study-in-california
#7
Nitya Rajeshuni, Emily E Johnston, Olga Saynina, Lee M Sanders, Lisa J Chamberlain
BACKGROUND: Patients with a terminal illness should have access to their chosen location of death. Cancer is the leading cause of non-accidental death among adolescents and young adults (AYAs; those aged 15-39 years). Although surveys have suggested that a majority of these patients prefer a home death, to the authors' knowledge, little is known regarding their barriers to accessing their preferred location of death. As a first step, the authors sought to determine, across a large population, 20-year trends in the location of death among AYA patients with cancer...
July 12, 2017: Cancer
https://www.readbyqxmd.com/read/28696044/practice-patterns-of-palliative-radiation-therapy-in-pediatric-oncology-patients-in-an-international-pediatric-research-consortium
#8
Avani Dholakia Rao, Qinyu Chen, Ralph P Ermoian, Sara R Alcorn, Maria Luisa S Figueiredo, Michael J Chen, Karin Dieckmann, Shannon M MacDonald, Matthew M Ladra, Daria Kobyzeva, Alexey V Nechesnyuk, Kristina Nilsson, Eric C Ford, Brian A Winey, Rosangela C Villar, Stephanie A Terezakis
BACKGROUND/OBJECTIVES: The practice of palliative radiation therapy (RT) is based on extrapolation from adult literature. We evaluated patterns of pediatric palliative RT to describe regimens used to identify opportunity for future pediatric-specific clinical trials. DESIGN/METHODS: Six international institutions with pediatric expertise completed a 122-item survey evaluating patterns of palliative RT for patients ≤21 years old from 2010 to 2015. Two institutions use proton RT...
July 11, 2017: Pediatric Blood & Cancer
https://www.readbyqxmd.com/read/28691671/bilateral-primary-ovarian-non-hodgkin-s-lymphoma-and-fertility-preservation-5-year-follow-up
#9
C Grigoriadis, A Tympa, A Chasiakou, S Baka, D Botsis, D Hassiakos
AIM: Primary ovarian non-Hodgkin's lymphoma is a very rare disease. Median age at diagnosis is estimated at 42 years, something that leads to fertility preservation issues in many cases. This was a case report study, presenting a rare case of bilateral primary ovarian non-Hodgkin's lymphoma. CASE REPORT: A 38-year old nulliparous woman, underwent exploratory laparotomy because of bilateral ovarian masses. Left salpingooophorectomy, partial omentectomy and excision of an ovarian mass of the right ovary was performed...
March 2017: Il Giornale di Chirurgia
https://www.readbyqxmd.com/read/28685821/pd-1-pd-l1-inhibitors-in-haematological-malignancies-update-2017
#10
REVIEW
Tomas Jelinek, Jana Mihalyova, Michal Kascak, Juraj Duras, Roman Hajek
The introduction of PD-1/PD-L1 pathway inhibitors is an important landmark in solid oncology with unprecedented practice-changing activity in various types of solid tumours. Amongst haematological malignancies, PD-1/PD-L1 inhibitors have been successful, so far, only in the treatment of classical Hodgkin lymphoma, which typically exhibits an over-expression of PD-1 ligands (PD-L1, PD-L2) due to alterations in chromosome 9p24.1. Such positive outcomes led to the FDA approval of nivolumab use in relapsed Hodgkin lymphoma in 2016 as the first haematological indication...
July 6, 2017: Immunology
https://www.readbyqxmd.com/read/28684378/utility-of-bone-marrow-biopsy-and-aspirate-for-staging-of-diffuse-large-b-cell-lymphoma-in-the-era-of-positron-emission-tomography-with-2-deoxy-2-fluorine-18-fluoro-deoxyglucose-integrated-with-computed-tomography
#11
Prakash Vishnu, Andrew Wingerson, Marie Lee, Margaret T Mandelson, David M Aboulafia
BACKGROUND: About one-third of patients with diffuse large B cell lymphoma (DLBCL) have lymphomatous bone marrow involvement (BMI) at the time of diagnosis, and bone marrow aspirate/biopsy (BMAB) is considered the gold standard to detect such involvement. [(18)F] fluorodeoxyglucose positron emission tomography combined with computed tomography (PET-CT), has become standard pretreatment imaging in DLBCL and may be a noninvasive alternative to BMAB to ascertain BMI. Prior studies have suggested that PET-CT scan may obviate the need for BMAB as a component for staging patients with newly diagnosed DLBCL, but this is not yet a standard of practice...
June 17, 2017: Clinical Lymphoma, Myeloma & Leukemia
https://www.readbyqxmd.com/read/28683503/focal-breast-lesions-in-clinical-ct-examinations-of-the-chest-a-retrospective-analysis
#12
Kathrin Barbara Krug, Christian Houbois, Olga Grinstein, Jan Borggrefe, Michael Puesken, Bettina Hanstein, Wolfram Malter, David Maintz, Martin Hellmich
Purpose Based on radiological reports, the percentage of breast cancers visualized as incidental findings in routine CT examinations is estimated at ≤ 2 %. In view of the rising number of CT examinations and the high prevalence of breast cancer, it was the goal of the present study to verify the frequency and image morphology of false-negative senological CT findings. Materials and Methods All first contrast-enhanced CT examinations of the chest in adult female patients carried out in 2012 were retrospectively included...
July 6, 2017: RöFo: Fortschritte Auf Dem Gebiete der Röntgenstrahlen und der Nuklearmedizin
https://www.readbyqxmd.com/read/28679373/a-comprehensive-overview-on-the-surgical-management-of-secondary-lymphedema-of-the-upper-and-lower-extremities-related-to-prior-oncologic-therapies
#13
REVIEW
Ramon Garza, Roman Skoracki, Karen Hock, Stephen P Povoski
Secondary lymphedema of the upper and lower extremities related to prior oncologic therapies, including cancer surgeries, radiation therapy, and chemotherapy, is a major cause of long-term morbidity in cancer patients. For the upper extremities, it is most commonly associated with prior oncologic therapies for breast cancer, while for the lower extremities, it is most commonly associated with oncologic therapies for gynecologic cancers, urologic cancers, melanoma, and lymphoma. Both non-surgical and surgical management strategies have been developed and utilized, with the primary goal of all management strategies being volume reduction of the affected extremity, improvement in patient symptomology, and the reduction/elimination of resultant extremity-related morbidities, including recurrent infections...
July 5, 2017: BMC Cancer
https://www.readbyqxmd.com/read/28675320/flow-cytometry-for-feline-lymphoma-a-retrospective-study-regarding-pre-analytical-factors-possibly-affecting-the-quality-of-samples
#14
Valeria Martini, Serena Bernardi, Priscilla Marelli, Marzia Cozzi, Stefano Comazzi
Objectives Flow cytometry (FC) is becoming increasingly popular among veterinary oncologists for the diagnosis of lymphoma or leukaemia. It is accurate, fast and minimally invasive. Several studies on FC have been carried out in canine oncology and applied with great results, whereas there is limited knowledge and use of this technique in feline patients. This is mainly owing to the high prevalence of intra-abdominal lymphomas in this species and the associated difficulty in the diagnostic procedures needed to collect the sample...
July 1, 2017: Journal of Feline Medicine and Surgery
https://www.readbyqxmd.com/read/28673332/a-multicenter-survey-of-first-line-treatment-patterns-and-gene-aberration-test-status-of-patients-with-unresectable-stage-iiib-iv-nonsquamous-non-small-cell-lung-cancer-in-china-ctong-1506
#15
Qing Zhou, Yong Song, Xin Zhang, Gong-Yan Chen, Dian-Sheng Zhong, Zhuang Yu, Ping Yu, Yi-Ping Zhang, Jian-Hua Chen, Yi Hu, Guo-Sheng Feng, Xia Song, Qiang Shi, Lu Lu Yang, Ping Hai Zhang, Yi-Long Wu
BACKGROUND: In recent years, systemic chemotherapy and molecular targeted therapy have become standard first-line treatments for locally advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC). The objective of this survey was to investigate first-line anticancer treatment patterns and gene aberration test status of patients with advanced nonsquamous NSCLC in China. METHODS: Patients included in this study had unresectable Stage IIIB/IV nonsquamous NSCLC and were admitted during August 2015 to March 2016 into one of 12 tertiary hospitals throughout China for first-line anticancer treatment...
July 3, 2017: BMC Cancer
https://www.readbyqxmd.com/read/28667319/infection-is-an-independent-predictor-of-death-in-diffuse-large-b-cell-lymphoma
#16
Claire Dendle, Michael Gilbertson, Tim Spelman, Rhonda L Stuart, Tony M Korman, Karin Thursky, Stephen Opat, Zoe McQuilten
To identify risk factors for infection in patients with diffuse large B cell lymphoma (DLBCL) undergoing rituximab, cyclophosphamide, vincristine, adriamycin and prednisolone (R-CHOP) treatment. All patients with DLBCL who received R-CHOP from 2004-2014 in a tertiary Australian hospital were identified and information collected from hospital admission data, laboratory results and medical record review. Infection was defined as hospitalisation with an ICD-10-AM diagnostic code for infection. Risk factors for infection and association between infection and survival were modelled using Cox proportional hazards regression...
June 30, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28666906/craniospinal-irradiation-prior-to-stem-cell-transplant-for-hematologic-malignancies-with-cns-involvement-effectiveness-and-toxicity-after-photon-or-proton-treatment
#17
Jillian R Gunther, Ahmad R Rahman, Wenli Dong, Zeinab Abou Yehia, Partow Kebriaei, Gabriela Rondon, Chelsea C Pinnix, Sarah A Milgrom, Pamela K Allen, Bouthaina S Dabaja, Grace L Smith
PURPOSE/OBJECTIVE(S): Craniospinal irradiation (CSI) improves local control of leukemia/lymphoma with central nervous system (CNS) involvement; however, for adult patients anticipating stem cell transplant (SCT), cumulative treatment toxicity is a major concern. We evaluated toxicities and outcomes for patients receiving proton or photon CSI before SCT. METHODS AND MATERIALS: We identified 37 consecutive leukemia/lymphoma patients with CNS involvement who received CSI before SCT at our institution...
May 10, 2017: Practical Radiation Oncology
https://www.readbyqxmd.com/read/28664772/bendamustine-hydrochloride-in-patients-with-b-cell-malignancies-who-have-comorbidities-is-there-an-optimal-dose
#18
Max J Gordon, Lionel D Lewis, Jennifer R Brown, Alexey V Danilov
The majority of patients with non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL) present with comorbidities. Many of them are poor candidates for intensive chemo-immunotherapy regimens, such as FCR (fludarabine, cyclophosphamide, rituximab). Still, most clinical trials aim to enroll 'fit' patients, who poorly represent the community oncology population. Areas covered: In the past decade, bendamustine hydrochloride, a cytotoxic agent with structural similarities to both alkylating agents and purine analogs, has received widespread use in therapy of NHL and CLL, and has demonstrated a relatively favorable toxicity profile...
July 10, 2017: Expert Review of Hematology
https://www.readbyqxmd.com/read/28659916/hla-bw4-i-80-isoform-differentially-influences-clinical-outcome-as-compared-to-hla-bw4-t-80-and-hla-a-bw4-isoforms-in-rituximab-or-dinutuximab-based-cancer-immunotherapy
#19
Amy K Erbe, Wei Wang, Patrick K Reville, Lakeesha Carmichael, KyungMann Kim, Eneida A Mendonca, Yiqiang Song, Jacquelyn A Hank, Wendy B London, Arlene Naranjo, Fangxin Hong, Michael D Hogarty, John M Maris, Julie R Park, M F Ozkaynak, Jeffrey S Miller, Andrew L Gilman, Brad Kahl, Alice L Yu, Paul M Sondel
Killer-cell immunoglobulin-like receptors (KIRs) are a family of glycoproteins expressed primarily on natural killer cells that can regulate their function. Inhibitory KIRs recognize MHC class I molecules (KIR-ligands) as ligands. We have reported associations of KIRs and KIR-ligands for patients in two monoclonal antibody (mAb)-based trials: (1) A Children's Oncology Group (COG) trial for children with high-risk neuroblastoma randomized to immunotherapy treatment with dinutuximab (anti-GD2 mAb) + GM-CSF + IL-2 + isotretinion or to treatment with isotretinoin alone and (2) An Eastern Cooperative Oncology Group (ECOG) trial for adults with low-tumor burden follicular lymphoma responding to an induction course of rituximab (anti-CD20 mAb) and randomized to treatment with maintenance rituximab or no-maintenance rituximab...
2017: Frontiers in Immunology
https://www.readbyqxmd.com/read/28648302/nephrotic-syndrome-with-cancer-immunotherapies-a-report-of-2-cases
#20
Abhijat Kitchlu, Warren Fingrut, Carmen Avila-Casado, Christopher T Chan, Michael Crump, David Hogg, Heather N Reich
Oncologic immunotherapies use a patient's immune response to eliminate tumor cells by modulation of immune checkpoints, including programmed cell death 1 (PD-1) and cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) proteins. Immune-mediated sequelae, including interstitial nephritis, have been reported; however, glomerular disease appears rare. We describe 2 cases of nephrotic syndrome in patients treated with these agents. Patient 1 received the anti-PD-1 antibody pembrolizumab for Hodgkin lymphoma. Following his second dose, he developed nephrotic syndrome and acute kidney injury...
June 22, 2017: American Journal of Kidney Diseases: the Official Journal of the National Kidney Foundation
keyword
keyword
63324
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"